title: Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.
abstract: A study was designed to determine the interactions, both clinical and pharmacokinetic, between methadone and lopinavir-ritonavir. Results demonstrated a 36% reduction in the methadone area under the plasma concentration-time curve after the introduction of lopinavir-ritonavir, with no coincident symptoms of opioid withdrawal and no requirement for methadone dose adjustment.
authors.affiliation: GenitoUrinary Medicine and Infectious Diseases Clinic, St. James's Hospital, Dublin, Ireland. Susan.Clarke@bmc.org
authors.forename: Susan
authors.initials: S
authors.lastname: Clarke
authors.forename: Fiona
authors.initials: F
authors.lastname: Mulcahy
authors.forename: Colm
authors.initials: C
authors.lastname: Bergin
authors.forename: Helen
authors.initials: H
authors.lastname: Reynolds
authors.forename: Nicola
authors.initials: N
authors.lastname: Boyle
authors.forename: Michael
authors.initials: M
authors.lastname: Barry
authors.forename: David J
authors.initials: DJ
authors.lastname: Back
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D061466:Lopinavir; D008297:Male; D008691:Methadone / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D009293:Opioid-Related Disorders / Q000209:etiology; D011744:Pyrimidinones / Q000494:pharmacology / Q000627:therapeutic use; D012367:RNA, Viral / Q000187:drug effects; D019438:Ritonavir / Q000494:pharmacology / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000209:etiology*
chemical_list: D000701:Analgesics, Opioid; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D012367:RNA, Viral; D061466:Lopinavir; D019438:Ritonavir; D008691:Methadone